SVN-SDN-14

A series of serotonin, dopamine and noradrenaline modulators under pre-clinical investigation by Solvonis. They are being assessed for potential to promote pro-social behaviour and offer an improved safety profile compared to existing treatments being developed for post-traumatic stress disorder (PTSD).

Pro-social behaviour is increasingly recognised as a key factor in addressing PTSD. Enhancing these behaviours may help individuals with PTSD overcome feelings of isolation, rebuild interpersonal relationships and engage more effectively in therapeutic interventions.